Sara Melton is a seasoned Life Science Executive with over 25 years of experience in building successful biotech companies and launching cardiovascular products. She has a proven track record in business development and capital raises for pre-commercial biotech ventures. Previously, Sara was a Founding Partner at Blue Effect Strategy Partners, specializing in go-to-market strategy and FDA approval processes. She also served as President of North America for Egetis Therapeutics, launching U.S. operations for the Swedish rare disease company. Sara holds an Executive MBA from Northwestern University's Kellogg School of Management and a Bachelor of Science from Eastern Michigan University. She received the Trailblazer Award from the National Organization for Rare Diseases for her work on CRESEMBA.